

Thirty-Day Episode of Care Spending Following Heart Failure **Hospitalization Among Medicare Beneficiaries with Heart Failure**

¹Yale University School of Medicine, Center for Outcomes Research (CORE), New Haven, CT, USA; ²Division of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ³Cytokinetics, Incorporated, Health Economics and Outcomes Research, South San Francisco, CA, USA

BACKGROUND

- Heart failure (HF) is a leading cause of morbidity and mortality in the United States and is one of the costliest conditions¹
- Total HF-related health care expenditures are projected to increase from \$31 billion in 2012 to \$70 billion by 2030¹
- The majority of these costs come from hospitalizations, which are the main contributor to HF-related expenditures for all age groups²

OBJECTIVE

• To characterize current Medicare payments for HF spanning the index hospitalization through 30 days post-discharge, a period during which patients are at particularly high risk for readmission, to find potential areas to improve the value of care


METHODS

- Using Medicare fee-for-service administrative claims data, patients \geq 65 years of age hospitalized with HF from 2016 to 2018 were identified with the following International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10) primary discharge diagnostic codes:
- Systolic HF (I50.2x and I50.4x)
- Diastolic HF (I50.3x)
- Hypertensive heart disease (HHD) with HF (I11.0)
- HHD with HF and chronic kidney disease (CKD) (I13.0 and I13.2)
- Comorbidities were identified using ICD-10 codes from Medicare claims within the year before HF admission
- Coding patterns over time across these four groups, mean 30-day episode-of-care spending overall, and proportion of total costs allocated to the index hospitalization and post-acute care were analyzed
- Temporal trends were assessed for hospitalization volume by diagnosis, costs (index hospitalization, post-acute period, and total 30-day payments), 30-day readmission rates, and trends of those outcomes over time

Nihar Desai,¹ Xin Xin,¹ Craig Parzynski,¹ Katherine Clark,² Samuel Reinhardt,² Ralph Riello,¹ Phil Sarocco,³ Tariq Ahmad¹

RESULTS

- Overall, 935,962 patients hospitalized with HF were included
- Many patients had a diagnosis of HHD with HF and CKD (Figure 1)
- The burden of comorbidities is high in this patient population (Table 1)



CKD, chronic kidney disease: HF, heart failure: HHD, hypertensive heart disease


Table 1. Demographics and clinical characteristics of Medicare patients hospitalized with HF

Standardized payments	Overall	Systolic HF	Diastolic HF	HHD with HF	HHD with HF and CKD
Total population, N (%)	935,962	178,603	165,156	226,929	365,274
	(100.0)	(19.1)	(17.6)	(24.2)	(39.0)
Age, mean (SD)	81.2 (8.5)	80.6 (8.4)	82.1 (8.5)	81.5 (8.6)	80.9 (8.4)
Female, n (%)	504,259	79,513	107,721	135,891	181,134
	(53.9)	(44.5)	(65.2)	(59.9)	(49.6)
Race, n (%)					
White	781,317	151,747	144,246	194,450	290,874
	(83.5)	(85.0)	(87.3)	(85.7)	(79.6)
Black	106,726	18,554	13,723	21,546	52,903
	(11.4)	(10.4)	(8.3)	(9.5)	(14.5)
Other	47,919	8,302	7,187	10,933	21,497
	(5.1)	(4.6)	(4.4)	(4.8)	(5.9)
Medicare/Medicaid dual eligibility, n (%)	160,115	27,545	29,696	36,422	66,452
	(17.1)	(15.4)	(18.0)	(16.1)	(18.2)
Comorbid conditions, n (%)					
Morbid obesity, other endocrine, metabolic, and nutritional disorders	848,504 (90.7)	157,084 (88.0)	147,708 (89.4)	201,824 (88.9)	341,888 (93.6)
Hypertension	782,781	145,737	142,216	191,990	302,838
	(83.6)	(81.6)	(86.1)	(84.6)	(82.9)
Other musculoskeletal and connective tissue disorders	703,711 (75.2)	127,675 (71.5)	128,524 (77.8)	164,789 (72.6)	282,723 (77.4)
Angina pectoris/old myocardial infarction	653,439	136,495	98,932	146,163	271,849
	(69.8)	(76.4)	(59.9)	(64.4)	(74.4)
Arrhythmias	635,763	123,325	111,496	147,198	253,744
	(67.9)	(69.0)	(67.5)	(64.9)	(69.5)
Renal failure	622,273	103,625	91,695	62,890	364,063
	(66.5)	(58.0)	(55.5)	(27.7)	(99.7)
Other gastrointestinal disorders	617,894	112,934	112,344	142,147	250,469
	(66.0)	(63.2)	(68.0)	(62.6)	(68.6)
Vascular or circulatory disease	500,306	92,583	88,263	108,131	211,329
	(53.5)	(51.8)	(53.4)	(47.6)	(57.9)
Diabetes	498,973	89,993	83,397	104,555	221,028
	(53.3)	(50.4)	(50.5)	(46.1)	(60.5)

Presented comorbid conditions are those with incidence > 50% overall. CKD, chronic kidney disease; HF, heart failure; HHD, hypertensive heart disease; SD, standard deviation

Changes in Admissions of HF Types Over Time

• There was a substantial increase over time in admissions coded for a primary diagnosis of HHD with HF with or without CKD (**Figure 2**)



CKD, chronic kidney disease; HF, heart failure; HHD, hypertensive heart diseas

Payment Trends

- Total estimated mean Medicare 30-day payments for HF care were approximately \$16.5 billion over the 3-year study period
- Payments varied across the HF diagnosis codes; the highest
- payments were for patients with HHD with HF and CKD (Table 2)

Table 2. Medicare 30-day episode payments by code

Standardized Payments, \$	Overall	Systolic HF	Diastolic HF	HHD with HF	HHD with HF and CKD
			Median (IQR)		
Total index	9,518 (6,871–10,610)	8,903 (6,545–10,656)	9,179 (6,530–10,373)	7,779 (6,206–9,813)	9,962 (9,332–11,104)
Total post- acute care	2,970 (705–11,384)	2,902 (630–11,031)	3,264 (814–12,049)	2,421 (560–10,237)	3,275 (829–11,810)
Total 30-day	13,330 (9,912–22,489)	13,087 (9,201–22,440)	13,143 (9,475–22,184)	11,328 (8,135–19,989)	14,750 (10,922–23,961)
			Mean (SD)		
Total index	10,500 (7,863)	10,735 (9,487)	9,619 (6,654)	8,979 (7,124)	11,729 (7,715)
Total post- acute care	7,126 (9,767)	7,060 (10,069)	7,411 (10,175)	6,469 (9,292)	7,438 (9,697)
Total 30-day	17,626 (12,641)	17,795 (13,876)	17,030 (12,341)	15,448 (11,855)	19,167 (12,396)

CKD, chronic kidney disease; HF, heart failure; HHD, hypertensive heart disease; IQR, interquartile range; SD, standard deviation

- Overall, payments remained fairly stable over the 3-year period, rising by about \$300 over the 3-year period (**Table 3**)
- Median payments for systolic HF rose steadily from 2016 to 2018 (Figure 3)
- In contrast, 30-day payments for HHD with HF and CKD decreased slightly each year from 2016 through 2018

Table	3
Standard Payment	
Total ind	¢
Total pos	
Total 30-	0
Total ind	
Total pos	
Total 30-	
IQR, interqua	
Figu	
t (\$	
SO	
0	
CKD, chronic	
CO	
• HF is	3

• A substantial change in coding patterns was observed between 2016 and 2018, resulting in an increase in HHD with HF and CKD Despite this, overall payments by year and by diagnosis largely remained stable

References 1. Heidenreich et al. (2013). Circ Heart Fail. 6(3):606–619. 2. Dunlay et al. (2011). Circ Cardiovasc Qual Outcomes. 4(1):68–75.

This study was funded by Cytokinetics, Incorporated. Editorial support was provided by Jennifer Giel, PhD and Richard Fay, PhD, CMPP on behalf of Evidence Scientific Solutions, Philadelphia, PA, and was funded by Cytokinetics, Incorporated.




3. Overall Medicare 30-day episode payments for HF by year

		• • •			
rdized nts, \$	2016	2017	2018		
	Median (IQR)				
dex	9,370 (6,622–10,574)	9,683 (7,123–10,730)	9,420 (7,630–10,508)		
ost-acute care	2,952 (699–11,371)	2,987 (703–11,485)	2,970 (713–11,292)		
)-day	13,046 (9,538–22,207)	13,530 (10,117–22,790)	13,369 (9,939–22,429)		
	Mean (SD)				
dex	10,214 (7,885)	10,707 (7,883)	10,550 (7,816)		
ost-acute care	7,105 (10,048)	7,165 (9,684)	7,106 (9,596)		
)-day	17,318 (12,888)	17,872 (12,600)	17,656 (12,454)		

rtile range; SD, standard deviation

re 3. Total 30-day episode payments by code by year



kidney disease; HF, heart failure; HHD, hypertensive heart disease

NCLUSIONS

responsible for substantial 30-day Medicare spending: approximately \$16.5 billion over 3 years

Acknowledgments

Disclosures

N Desai works under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures used for public reporting and pay for performance programs. He reports research grants and consulting for Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, Incorporated, Medicines Company, Novartis, Relypsa, and scPharmaceuticals. R Riello is a consultant for Alexion, AstraZeneca, Janssen, Johnson & Johnson, Portola, and received a research grant from AstraZeneca. T Ahmad is a consultant for Amgen and Cytokinetics, Incorporated. X Xin, K Clark, S Reinhardt, and C Parzynski have no disclosures to report. P Sarocco is an employee of Cytokinetics, Incorporated.